Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
-
br Occurrence of Inosine in
2023-03-02
Occurrence of Inosine in RNA Inosine is widespread among various types of RNAs including transfer RNA (tRNA), ribosomal RNA (rRNA), messenger RNA (mRNA), long noncoding RNA (lncRNA), and microRNA (miRNA). Within these RNAs, inosine can appear in different locations as well. Table 1 lists examples
-
Our initial approach to identify hits was two pronged and
2023-03-02
Our initial approach to identify hits was two-pronged and included a high-throughput screening (HTS) campaign of the OSI nkcc inhibitor library as well as a virtual screening (VS) campaign, utilizing a publically available crystal structure of ACK1 (PDB code: ). A tolerance for protein flexibility
-
Despite hydrolysis with commercial enzymes like
2023-03-02
Despite hydrolysis with commercial enzymes like trypsin, pepsin, Alcalase, Flavourzyme and Thermolysin have been used to digest parent proteins and generate peptides, microbial fermentation by proteolytic species has also proved to be a successful strategy (Fakhfakh et al., 2013, Jemil et al., 2016,
-
CYP A is one of the key metabolizing
2023-03-02
CYP3A4 is one of the key metabolizing acetylcholine inhibitors of the cytochrome P450 (CYP) superfamily of heme-containing monooxygenases. As the CYP family of enzymes plays important roles not only in the xenobiotic metabolism and detoxification of a large number of drugs, but also in the biosynthe
-
In previous years evidence emerged that inferred secondary
2023-03-02
In previous years, evidence emerged that inferred secondary metabolites in plants might exhibit a potential arginase inhibition [36]. In a recent study, Pham and co-workers showed the inhibitory activity of chlorogenic meclofenamate (7) and piceatannol (8) (Fig. 3b) on mammalian arginase with IC50s
-
br Materials and method br Results and discussion br Conclus
2023-03-01
Materials and method Results and discussion Conclusion The adsorption behaviors of 5 antibiotics on 5 types of microplastic particles were investigated using batch type experiments. Our results showed that adsorption capacities varied among antibiotics, plastic types, and environmental cond
-
Detailed analysis of the dose dependence of A
2023-03-01
Detailed analysis of the dose dependence of Aβ effects revealed that at low amounts, Aβ can also act as a positive regulator of presynaptic activity, enhancing the neurotransmitter release probability and increasing the neuronal excitability [2]. The facilitator effects of low Aβ dose on excitatory
-
and LO are members of the lipoxygenase family
2023-03-01
5- and 12/15-LO are members of the lipoxygenase family that convert arachidonic AZD1390 into lipid mediators such as leukotriene B4 (LTB) and 12()-hydroxyeicosatetraenoic acid (HETE) and 15()-HETE, respectively. Evidence from several in vitro and in vivo studies has shown that activation of the 5- a
-
Guvacoline hydrobromide A limitation of the NIA
2023-03-01
A limitation of the 2011 NIA-AA recommendations was that biomarkers were grouped into just two categories—amyloid and tau-related neurodegeneration. Tauopathy and neurodegeneration were placed into the same biomarker category. In persons with only AD, it is reasonable to assume that neurodegeneratio
-
Since the publication of the guidelines data
2023-03-01
Since the publication of the 2011 guidelines, data have continued to accumulate indicating that the cognitive decline in AD occurs continuously over a long period [6–8], and that progression of biomarker measures is also a continuous process that begins before symptoms [9–14]. Thus, the disease is n
-
br Hypothesis The hypothesis is that
2023-03-01
Hypothesis The hypothesis is that AhR in skin diseases could be an objective of study for future dermatological therapies. Both stimulation and inhibition of the receptor might have significant influences on neoplastic or inflammatory skin diseases. However, at present the functions of AhR are un
-
br Introduction Clinical manifestations of Alzheimer s disea
2023-03-01
Introduction Clinical manifestations of Alzheimer's disease (AD) are mainly characterized by progressive intellectual deterioration, memory impairment, cognitive impairment, and psychiatric symptoms. The pathogenesis of AD remains unclear, mainly containing genetic factors, neurotransmitter disor
-
br Expression of ADK in the normal brain In
2023-03-01
Expression of ADK in the normal brain In adult brain, ADK is primarily expressed in astrocytes. Immunocytochemical analysis of adult rat and mouse KP372-1 revealed predominant astrocytic expression throughout the hippocampus and cortex. Two isoforms of ADK have been identified in mammals, a long
-
ACK can be localized to
2023-03-01
ACK1 can be localized to clathrin-coated vesicles [1]. The association of SNX9 with synaptojanin-1 would suggest the two cooperate during endocytosis at the synapse by coupling the sorting nexin to changes in phospholipid composition. ACK1 in turn negatively regulates the association of SNX9 with ta
-
Based on our previous work and
2023-03-01
Based on our previous work [13] and the observation that SNX9 is a partner for ACK, we have investigated interactions involving the SH3 domain of SNX9, and identified for the first time synaptojanin-1 as an alternate partner. This SH3 domain can bind a single site in ACK1, but multiple sites in the
14853 records 277/991 page Previous Next First page 上5页 276277278279280 下5页 Last page